Source - LSE Regulatory
RNS Number : 0264B
Advanced Oncotherapy PLC
05 October 2020
 

5 October 2020

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Grant of LTIP Options

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, today announces that its Remuneration Committee has approved the grant of share options (the "Options") over a total of 24,000,000 new ordinary shares of 25 pence each ("Ordinary Shares") to members of the management team.

 

The Options granted include 13,500,000 Options that have been granted to the Executive Directors. 6,500,000 have been awarded to Nicolas Serandour (Chief Executive Officer), 5,500,000 to Dr Michael Sinclair (Executive Chairman) and 1,500,000 to Prof. Steve Myers (Executive Director and ADAM Executive Chairman). A further 10,500,000 Options have been granted to other employees of the Company (including two persons discharging managerial responsibilities ("PDMRs").

 

The Options have been granted at an exercise price of 50 pence per share, a premium of c.61.9% to the weighted average share price over the past 30 days and a premium of 100% to the issue price of the fundraising  completed by the Company in May 2020. The Options have a five-year term, expiring on 5 October 2025 and will vest at the discretion of the Remuneration Committee, based on the achievement of the following vesting conditions:

 

·      the LIGHT system is fully operational at 230MeV;

·      the first patient has been treated;

·      the LIGHT system has been certified; and

·      the Company's share price has been in excess of £1.00 for 30 consecutive calendar days.

 

The award of the Options is consistent with the Remuneration Committee's policy of aligning the interests of key personnel and shareholders through appropriate incentive schemes, including the award of shares and share options. The vesting of the Options is subject to the continued employment of employees. Any shares that are issued by the Company as a result of the exercise of vested Options will be required to be held by the optionholders until 5 October 2023.

 

Following the grant of the Options, the Company has options outstanding over 34,649,342 new Ordinary Shares, which represents approximately 11.3 per cent. of the Company's issued ordinary share capital.

 

Details of the Option grants to PDMRs (including the Executive Directors) are set out in the requisite disclosure forms at the end of this announcement.

 

- ENDS -

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad and Joint Broker)


Nick Athanas / Liz Kirchner (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Broking)

Tel: +44 (0) 20 3328 5656



SI Capital Ltd (Joint Broker)


Nick Emerson

Tel: +44 (0) 1483 413 500

Jon Levinson

Tel: +44 (0) 20 3871 4066



FTI Consulting (Financial PR & IR)

advancedoncotherapy@fticonsulting.com

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Michael Sinclair (Director)

 

Nicolas Serandour (Director)

 

Steve Myers (Director)

 

Ed Lee (PDMR)

 

Bérengère Pons-Chabord (PDMR)

 

2

Reason for the notification

a)

Position/status

See 1 a) above

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Advanced Oncotherapy plc

b)

LEI

213800LUDHZOG3YT6C82

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of 25p each in Advanced Oncotherapy plc

 

Identification code (ISIN) for Advanced Oncotherapy plc ordinary shares: GB00BD6SX109

 

b)

Nature of the transaction

Grant of options over new ordinary shares

Price: 50p

c)

Price(s) and volume(s)

PDMR

Volume(s)

Michael Sinclair (Director)

 

Nicolas Serandour (Director)

 

Steve Myers (Director)

 

Ed Lee (PDMR)

 

Bérengère Pons-Chabord (PDMR)

 

5,500,000

 

6,500,000

 

1,500,000

 

2,500,000

 

1,000,000

 

d)

Aggregated information

- Aggregated volume

- Price

 

n/a

e)

Date of the transaction

5 October 2020

 

f)

Place of the transaction

outside of a trading venue - grant of options

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKQBPCBDDPKK
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.